Standort in Gefahr: Absagen für den Investitionsgipfel: Wirtschaftsbosse kritisieren deutsche Industriepolitik
Die Bundesregierung wirbt mit dem „Invest in Germany“-Gipfel um Vertrauen und Geld internationaler Unternehmen. Doch viele äußern sich kritisch – Pharmachefs sagen sogar ihre Teilnahme ab.
As the pivotal investors' event hosted by the German government looms, unease is brewing in several industries. Several key energy laws have been delayed for months, leaving businesses feeling uncertain. Meanwhile, the pharmaceutical sector is grappling with health sector austerity measures, causing frustration.
In a bid to signal that investments are welcome and that Germany is an attractive location for them, Chancellor Friedrich Merz and his cabinet have invited domestic and foreign companies to attend the "Invest in Germany" summit with Martin Blessing, the country's investment envoy. The summit is scheduled for Monday and Tuesday, and many CEOs will have the opportunity to meet personally with the chancellor and ministers.
Yves Meyer-Bülow, a partner at the infrastructure investor I Squared, believes that Germany has a historic opportunity to make its infrastructure a competitive advantage once again. After two decades of insufficient public investment, there is a significant backlog to address. Similarly, Roman Waleczek, managing director of financial services firm Rothschild, says that Germany's industrial location offers significant investment opportunities, especially in the areas of scale and modernization. The "Invest in Germany Summit" aims to send an important signal in this regard.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
